3rd ESTRO Forum 2015 S621 was found in 21 patients (67.8%) and stable disease (SD) was observed in 10 cases (32.2%). SD after chemotherapy was reported more often in patients qualified to high expression of βT-II, whereas PR in the group of low protein expression (p=0.004). The increase in Histoscore (HS) parameter obtained from the computer image analysis was correlated with the observed lower regression of the tumor (r=-0.43, p=0.017). In patients with SD effect observed after induction

more »

... herapy the mean value of HS was 109.5 whereas in the PR group the mean value of HS was 28.34. No correlation between the response to radiotherapy and βT-II expression was found (p=0.92). The difference in 1-year OS and PFS was not shown for the patients from neither the high or low βT-II expression (OS 75% vs 63%; p=0.69, PFS 63% vs 58%; p=0.69). Conclusions: The βT-II protein expression level in tumor tissue is a predictive factor for clinical response to taxanebased neoadjuvant chemotherapy in LASHNC. In the case of high βT-II expression the most probable effect of chemotherapy is tumor stabilization. Low βT-II expression level may be a parameter used to select the patients with prognozed good response to TPF chemotherapy. In these patients realization of radiotherapy may be easier without the risk of delayed definitive treatment.